Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Zanubrutinib in Primary Cold Agglutinin Disease. CaZa Study

NCT06067048 is registered in ClinicalTrials.gov with Stichting Hemato-Oncologie voor Volwassenen Nederland as lead sponsor.

NCT NCT06067048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06067048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Zanubrutinib in Primary Cold Agglutinin Disease. CaZa Study
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 26, 2024
Completion date
November 1, 2028
Enrollment
25 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma